Verve Therapeutics Stock Last Dividend Paid
| VERV Stock | USD 7.01 0.15 2.09% |
Verve Therapeutics fundamentals help investors to digest information that contributes to Verve Therapeutics' financial success or failures. It also enables traders to predict the movement of Verve Stock. The fundamental analysis module provides a way to measure Verve Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Verve Therapeutics stock.
Verve | Last Dividend Paid |
Verve Therapeutics Company Last Dividend Paid Analysis
Verve Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Verve Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Verve Therapeutics is extremely important. It helps to project a fair market value of Verve Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Verve Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Verve Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Verve Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Verve Dividend Paid And Capex Coverage Ratio
Dividend Paid And Capex Coverage Ratio |
|
Based on the recorded statements, Verve Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Verve Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verve Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verve Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Verve Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.29) % | ||||
| Current Valuation | 137.53 M | ||||
| Shares Outstanding | 84.66 M | ||||
| Shares Owned By Insiders | 1.77 % | ||||
| Shares Owned By Institutions | 97.75 % | ||||
| Number Of Shares Shorted | 17.08 M | ||||
| Price To Earning | 5.45 X | ||||
| Price To Book | 1.19 X | ||||
| Price To Sales | 24.85 X | ||||
| Revenue | 11.76 M | ||||
| Gross Profit | (128.15 M) | ||||
| EBITDA | (217.67 M) | ||||
| Net Income | (200.07 M) | ||||
| Cash And Equivalents | 293.56 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 74.91 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 11.55 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | (149.55 M) | ||||
| Short Ratio | 12.66 X | ||||
| Earnings Per Share | (2.46) X | ||||
| Target Price | 26.2 | ||||
| Number Of Employees | 255 | ||||
| Beta | 1.76 | ||||
| Market Capitalization | 606.19 M | ||||
| Total Asset | 752.69 M | ||||
| Retained Earnings | (544.3 M) | ||||
| Working Capital | 600.94 M | ||||
| Net Asset | 752.69 M |
About Verve Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verve Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verve Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verve Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.